Imunon Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
IMNN$0.88+4.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
1. FINANCIAL STATEMENTS
The following is a list of the consolidated financial statements of Imunon, Inc. filed with this Annual Report, together with the reports of our independent registered public accountants and Management’s Report on Internal Control over Financial Reporting.
| Page | |
| REPORTS | |
|---|---|
| Reports of Independent Registered Public Accounting Firm | F-1 |
| FINANCIAL STATEMENTS | |
| Consolidated Balance Sheets | F-3 |
| Consolidated Statements of Operations | F-5 |
| Consolidated Statements of Comprehensive Loss | F-6 |
| Consolidated Statements of Cash Flows | F-7 |
| Consolidated Statements of Changes in Stockholders’ Equity | F-9 |
| NOTES TO CONSOLIDATED FINANCIAL STATEMENTS | F-11 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.